Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00112827 · OUTCOME

Overall Survival

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma · Source last updated 2025-06-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
From date of treatment until the date of death from any cause, assessed up to 14 years

What was measured

Estimated using the product-limit method of Kaplan and Meier. Event defined as death due to any cause.

Analysis population: Overall survival was calculated for aggregated arms, due to small number of patients in most treatment arms.

Groups in this outcome

Treatment Arm

See Detailed Description total marrow irradiation: Undergo irradiation escalating according to the following schedule 1000cGy, 1200cGy, 1400cGy, 1600cGy, 1800cGy melphalan: Given IV peripheral blood stem cell transplantation: Undergo transplantation filgrastim: Given IV fluorescence in situ hybridization: Correlative studies cytogenetic analysis: Correlative studies cyclophosphamide: Given IV autologous-autologous tandem hematopoietic stem cell transplantation: Undergo transplantation lenalidomide: Given orally

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment Arm54

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment Arm95.8Not reported52.4NAUpper 95% confidence interval was not reached.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Upper 95% confidence interval was not reached.
        group Id
        OG000
        lower Limit
        52.4
        upper Limit
        NA
        value
        95.8
denoms
  1. counts
    1. group Id
      OG000
      value
      54
    units
    Participants
description
Estimated using the product-limit method of Kaplan and Meier. Event defined as death due to any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    See Detailed Description total marrow irradiation: Undergo irradiation escalating according to the following schedule 1000cGy, 1200cGy, 1400cGy, 1600cGy, 1800cGy melphalan: Given IV peripheral blood stem cell transplantation: Undergo transplantation filgrastim: Given IV fluorescence in situ hybridization: Correlative studies cytogenetic analysis: Correlative studies cyclophosphamide: Given IV autologous-autologous tandem hematopoietic stem cell transplantation: Undergo transplantation lenalidomide: Given orally
    id
    OG000
    title
    Treatment Arm
param Type
MEDIAN
population Description
Overall survival was calculated for aggregated arms, due to small number of patients in most treatment arms.
reporting Status
POSTED
time Frame
From date of treatment until the date of death from any cause, assessed up to 14 years
title
Overall Survival
type
PRIMARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice